Cell Isolation/Cell Separation Market Is Expected To Reach USD 16.4 Billion By 2025 : Grand View Research Inc.

San Francisco, 1 August 2019: The Report Cell Isolation/Cell Separation Market Analysis By Product (Consumables, Instruments), By Cell Type (Human, Animal), By Technique (Centrifugation, Surface Marker, Filtration), By Application, And Segment Forecasts, 2018 – 2025

The global cell isolation/cell separation market is expected to reach a value of USD 16.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing demand for biopharmaceuticals including antibodies, proteins, vaccines, and drugs is the most important factor that drives the market growth during the forecast period. Biopharmaceuticals development involves the application of various life science products such as centrifuges, cell separator systems, flow cytometers, filtration systems, and consumables. Thus, the demand for advanced cell isolation products by biotechnology and biopharmaceutical companies is increasing, which is expected to boost the market growth.

Rising funding by biotechnology companies and government for cell-based research is another major factor driving the growth of the cell isolation/cell separation market. For instance, National Institutes of Health invested around USD 1,429 million for stem cells research in 2015. Stem cell therapy is the most promising technique to treat severe medical conditions such as cancer, cardiovascular disease, brain disease, and blood disease. Thus, the biotechnology companies are adopting advanced cell separation products for the research and development of stem cells.

Access Research Report of Cell Isolation/Cell Separation Market @ www.grandviewresearch.com/industry-analysis/cell-isolation-cell-separation-market

Further key findings from the study suggest:

• Consumables product segment was the largest revenue-generating segment of the market in the year 2016.
• Consumables is expected to uphold its dominance during the forecast period owing to repetitive purchase of these products for research and diagnostics application
• The human cells segment was the largest revenue grossing segment of the sector in 2016, and is expected to grow at fastest rate due to growing demand of isolated human cell in therapeutics, research, and biopharmaceuticals production
• In 2016, the centrifugation technique segment accounted for the largest share in the overall market, owing to its wide application for manufacturing of biopharmaceutical drugs, vaccines, proteins, and antibodies
• In 2016, North America dominated the overall market with the largest revenue share due to the existence of major biopharmaceutical companies and research laboratories in this region
• Asia Pacific is projected to witness the highest CAGR over the forecast period, owing to the mounting investments in cell-based research and rapidly booming biotechnology industry in this region
• Some of the key players include Thermo Fisher Scientific, Inc.; BD Biosciences; GE Healthcare; Beckman Coulter, Inc.; Merck KGaA; Terumo BCT; STEMCELL Technologies Inc.; and Bio-Rad Laboratories, Inc.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the cell isolation/cell separation market on the basis of product, cell type, technique, application, end-use, and region:

Cell Isolation/Cell Separation Product Outlook (Revenue, USD Million; 2014 – 2025)

• Consumables
  • Reagents, kits, media, and sera
  • Beads
  • Disposables
• Instruments
• Centrifuges
• Flow cytometers
• Filtration systems
• Magnetic-activated cell separator systems

Cell Isolation Cell Separation Cell Type Outlook (Revenue, USD Million; 2014 – 2025)

• Human cells
• Animal cells

Cell Isolation Cell Separation Technique Outlook (Revenue, USD Million; 2014 – 2025)

• Centrifugation
• Surface marker
• Filtration

Cell Isolation Cell Separation Application Outlook (Revenue, USD Million; 2014 – 2025)

• Biomolecule isolation
• Therapeutics
• Stem cell research
• Cancer research
• Tissue regeneration
• In-vitro diagnostics

Cell Isolation Cell Separation End-Use Outlook (Revenue, USD Million; 2014 – 2025)

• Research laboratories and institutes
• Biotechnology and biopharmaceutical companies
• Cell banks
• Hospitals and diagnostic laboratories

Cell Isolation Cell Separation Regional Outlook (Revenue, USD Million; 2014 – 2025)

• North America
• Europe
• Asia Pacific
• Latin America
• MEA

Access Press Release of Cell Isolation/Cell Separation Market @ www.grandviewresearch.com/press-release/global-cell-isolation-cell-separation-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Electronic Clinical Outcome Assessment (eCOA) Solutions Market Anticipated To Expand At USD 2.16 Billion By 2025 : Grand View Research Inc.

San Francisco, 1 August 2019: The Report Electronic Clinical Outcome Assessment (eCOA) Solutions Market Analysis By Delivery Mode (Web-hosted, Licensed Enterprise, Cloud-based), By End Use (Hospitals, Biotech/Pharma Organizations), & Segment Forecasts, 2018 – 2025

The global electronic clinical outcome assessment (eCOA) solutions market is expected to reach USD 2.16 billion by 2025, according to a new report by Grand View Research, Inc. The complexity in healthcare information management is anticipated to fuel the demand for eCOA solutions in coming years. These solutions deliver accurate and timely health information and reduce burden of patients enrolled in clinical trials.

eCOA measures overall mental state, patient symptoms, and the progression of a disease. Electronic diaries and electronic Patient Reported Outcomes (ePRO) are a part of eCOA platforms. Electronic diaries help document patient response. These are used as support systems for ePRO. In all the applications of clinical outcome assessment systems, the compliance rates are more than 90%, which helps accelerate research procedures.

In addition, assessment systems help detect probable adverse conditions in advance for patients, which is crucial for taking preventive measures to avoid adverse effects in future. The ePRO platforms transfer real-time data from the patients to healthcare professionals for accurate decision-making and better evaluation of a patient’s health. Thus, the adoption of these platforms is expected to grow in near future.

Growing adoption of software solutions during research studies, high R&D expenditure by pharmaceutical companies, favorable government grants to support clinical trials, and widening base of potential customers are some of the key contributing factors for market growth.

Access Research Report of Electronic Clinical Outcome Assessment (eCOA) Solutions Market @ www.grandviewresearch.com/industry-analysis/electronic-clinical-outcome-assessment-ecoa-solutions-market

Further Key Findings From the Study Suggest: 

• Rising adoption of technologically advanced wearable and handheld medical devices helps capture clinical outcomes electronically, further making the medical information assessment easier
• The core advantage of web-based services is ability to access information from remote locations using only one computer or monitoring device in healthcare settings
• Cloud-based solutions are anticipated to grow at an exponential rate owing to integrated features that include flexibility, high accessibility, negligible handling costs, and easy data backup
• Contract research organizations dominated the market as major pharmaceutical companies are focused on reducing expenditure on clinical trials
• North America held the largest market share owing to the local presence of well-established market players coupled with large number of ongoing research in this region
• Asia Pacific market is expected to show fastest growth over the forecast period owing to the availability of a large number of contract research firms offering eCOA platforms to large pharmaceuticals
• The companies are making significant investments to implement eClinical solutions in order to manage medical information, owing to the benefits it offers

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/healthcare-it

Grand View Research has segmented the eCOA solutions market on the basis of the delivery mode, end use, and region:

eCOA Solutions Delivery Mode Outlook (Revenue, USD Million, 2014 – 2025)

• Web hosted
• Licensed enterprise
• Cloud based

eCOA Solutions End-use Outlook (Revenue, USD Million, 2014 – 2025)

• Hospitals
• CROs
• Academic Institutes
• Pharma & Biotech Organizations
• Medical Device Manufacturers

eCOA Solutions Regional Outlook (Revenue, USD Million, 2014 – 2025)

• North America
• Europe
• Asia Pacific
• Latin America
• MEA

Access Press Release of Electronic Clinical Outcome Assessment (eCOA) Solutions Market @ www.grandviewresearch.com/press-release/global-electronic-clinical-outcome-assessment-ecoa-solutions-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Liposomal Doxorubicin Market Estimated To Flourish At USD 1.39 Billion By 2024 : Grand View Research Inc.

San Francisco, 1 August 2019: The Report Liposomal Doxorubicin Market Analysis By Product, (J&J [Doxil/Caelyx], Sun Pharma [Lipodox], Teva [Myocet], Others), By Application, (Multiple Myeloma, Kaposi Sarcoma, Ovarian, Breast, Kidney Cancer), And Segment Forecasts, 2018 – 2024

The global liposomal doxorubicin market is expected to reach a value of USD 1.39 billion by 2024, according to a new report by Grand View Research, Inc. The presence of various pipeline products awaiting approval by the U.S. FDA and European Medicines Agency is one of the key attributes of this market. The first liposomal doxorubicin formulation was launched in 1995, namely Doxil/Caelyx by Janssen Products and LP & Myocet by Teva Pharmaceutical Laboratories. Doxil, the brand name of liposomal doxorubicin, is under development, and post its commercialization, the product is expected to create significant value over the next 3 to 4 years.

The increasing U.S. FDA approval for drug production is also anticipated to boost the market. The increasing indication of these drugs for various conditions such as AIDS-related Kaposi sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand. The technological advancements in the drugs formulations to overcome the adverse effects on health and also introduction of various types of medication delivery systems, such as coated nanoparticles, are some of the pivotal factors impelling the demand for the drug.

Liposomal doxorubicin is primarily approved for the treatment of myeloma, Kaposi sarcoma, and ovarian cancer. However, due to its wide usage in other conditions as well, in 2015, breast cancer accounted for the maximum revenue of 21.2%. The increasing prevalence of breast cancer is leading to growing demand for chemotherapy treatment, which accounts for the majority of revenue share. Besides breast carcinoma, ovarian cancer, multiple myeloma, and liver cancer also held a significant share in 2015. The use of doxorubicin for liver carcinoma treatment is rapidly growing, and this application is expected to grow with the fastest CAGR of 7.8% over the forecast period.

Access Research Report of Liposomal Doxorubicin Market @ www.grandviewresearch.com/industry-analysis/liposomal-doxorubicin-market

Further key findings from the study suggest:

• The increasing number of mergers & acquisitions and partnerships for clinical trials on technologically advanced doxorubicin formulations will boost market growth
• Increasing investment in Asia Pacific pertaining to the R&D, improving healthcare infrastructure, and heightened patient cognizance regarding targeted cancer therapies and chemotherapy will drive regional market growth
• Key players operating in the market are Janssen Products; LP; Teva Pharmaceuticals; Sun Pharmaceutical Industries Ltd.; Pfizer, Inc.; Cipla, Inc.; Cadila Pharmaceuticals; and SRS Pharmaceuticals Pvt. Ltd.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the liposomal doxorubicin market by product, application, and region:

Liposomal Doxorubicin Product outlook (Market revenue in USD Million, 2013 – 2024)

• J&J (Doxil/Caelyx)
• Sun Pharma (Lipodox)
• Teva (Myocet)
• Others

Liposomal Doxorubicin Application Outlook (Market revenue in USD Million, 2013 – 2024)

• Ovarian Cancer
• Multiple Myeloma
• Kaposi Sarcoma
• Leukemia
• Bone Sarcoma
• Breast Cancer
• Endometrial Cancer
• Gastric Cancer
• Liver Cancer
• Kidney Cancer
• Other Cancer

Liposomal Doxorubicin Regional Outlook (Market Revenue in USD Million, 2013 – 2024)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Access Press Release of Liposomal Doxorubicin Market @ www.grandviewresearch.com/press-release/global-liposomal-doxorubicin-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

 

 

Glucose Biosensor Market Size Is Anticipated To Reach USD 31.0 Billion By 2022 : Grand View Research Inc.

San Francisco, 1 August 2019: The Report Glucose Biosensor Market Size & Forecast By End-use (Hospitals, Homecare Diagnostics, Research Institutes, Diagnostic Centers, Clinics), By Region (U.S., UK, Germany, China, India, Brazil, Saudi Arabia, South Africa) And Trend Analysis From 2012 – 2022

Global Glucose Biosensor Market is expected to reach USD 31.0 billion by 2022, according to a new report by Grand View Research Inc. The global Glucose Biosensor Market is anticipated to witness lucrative growth during the period of 2015 to 2022.

Some key factors attributing to the growth of this market include the increasing incidence of diabetes across the globe, development of technologically advanced products, growing demand for minimally and non-invasive products, patient awareness levels, and the need for early diabetes detection. However, presence of other alternatives for management of the diabetes, such as laboratory methods is expected to restrict market growth.

The glucose biosensors industry by end-use is segmented on the basis of its use in hospitals, homecare diagnostics, and others including research institutes, diagnostics, and clinical laboratories. The homecare diagnostics Glucose Biosensor Market is projected to flourish over the forecast period. Ease-of-use, quick results, and low costs of the tests are some aspects supporting market growth. On the other hand, the hospital-based Glucose Biosensor Market is projected to grow at a significant CAGR of 10.3% during the period 2015 to 2022.

Access Research Report of Glucose Biosensor Market @ www.grandviewresearch.com/industry-analysis/glucose-biosensors-market

Further key findings from the study suggest:

• North America led the market, in terms of value, with a share of about 37% in 2015. High disease burden and the subsequent need to curb associated healthcare expenditure in the U.S., has resulted in this country account for a large revenue share of the North American market in 2014. According to the Centers of Disease Control (CDC), around 22.3 million people in the U.S. were estimated to be diagnosed with diabetes in the year 2013.
• Asia Pacific is anticipated to witness lucrative growth during the forecast period. This market is projected to grow rapidly during the period 2015 to 2022. China and India are expected to spearhead market growth in this region.
• The homecare diagnostics Glucose Biosensor Market was the largest in 2014. The segment is anticipated to grow at a rapid CAGR during the forecast period. As of 2015, the market was led by North America owing to the region’s highest disease burden and homecare diagnostics adoption rates.
• The Glucose Biosensor Market comprises several local as well as global players. Some major players of this industry include Roche, Bayer and LifeScan, Inc..

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented the global Glucose Biosensor Market on the basis of end-user application and region:

Glucose Biosensors End-use Outlook (Revenue, USD Million, 2012 – 2022)

• Hospitals
• Homecare Diagnostics
• Others

Biosensors Regional Outlook (Revenue, USD Million, 2012 – 2022)

• North America
• Europe
• Asia Pacific
• Latin America
• MEA

Access Press Release of Glucose Biosensor Market @ www.grandviewresearch.com/press-release/global-glucose-biosensor-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Nanoparticles – Metal & Metal Oxides Market Worth $ 80.74 Billion By 2025 : Grand View Research Inc.

San Francisco, 1 August 2019: The Report Nanoparticles – Metal & Metal Oxides Market In Healthcare By Type (Gold, Silver, Iron Oxide, Alumina, Gadolinium, Cerium), By Application (In-vivo Imaging, Targeted Drug Delivery, Proton Therapy, In-vitro assays), & Segment Forecasts, 2018 – 2025

The global nanoparticles – metal & metal oxides market in healthcare is anticipated to reach USD 80.74 billion by 2025, according to a new report by Grand View Research, Inc. Several nanotechnologies based medicines have been put forward for approval by the FDA which is anticipated to propel growth.

Success of nanomedicine has prompted the development of enhanced nanomaterials for clinical applications with particular emphasis in therapy and diagnostics. This has resulted into the significant production of metal oxide particles that hold potential utility in human medicine.

Remarkable evolution has been made in nanoparticle based medicines for theranostic applications in disease management. Diverse metals have been used for development of medicines with a promise to optimize the efficacy of nanomedicines and to improve the current standard of medical and clinical practices.

These particles are recognized to have major applications in drug delivery, diagnostic products, biomarker discovery, and product packaging. Widespread application spectrum of these particles in maintaining human health is expected to dramatically impact the progress of this market in the coming years.

Moreover, metal oxides are observed to have significant role in cancer treatment. Nanoparticle-augmented systems enable high-concentration targeted drug delivery to cancer cells, which in turn, is expected to enhance the usage rate of metal nanoparticles for cancer treatment. Development of drug delivery strategies using nanoparticle approaches are expected to bring about changes effective for cancer treatment.

However, prolonged exposure of nanoparticles adversely affects the human health as well environment thereby restraining their adoption rate. These products are involved in autophagy, oxidative stress, lysosome dysfunction, and the activation of certain signaling pathways, thereby exhibiting toxicity for human health.

Access Research Report of Nanoparticles – Metal & Metal Oxides Market @ www.grandviewresearch.com/industry-analysis/nanoparticles-metal-oxides-in-healthcare-market

Further key findings from the report suggest:

• Presence of untapped potential in alumina and alumina oxide particles is anticipated to create immense opportunities
• Aluminum oxide in combination with polymeric membranes is studied for enhancement of drug delivery owing to its high porosity property displayed in the membranes
• This enhanced efficacy of the membrane performance by the addition of alumina nanoparticles to polymeric membranes is projected to increase its adoption
• Approval of various nanoparticle composition and surface properties for clinical diagnostics and treatment of viral infections is anticipated drive market demand
• In-vivoimaging dominated the market with respect to revenue share
• Use of antibody conjugated to Au nanorods Raman spectrum with polarized, sharpened, and enhanced results can be attributed for larger revenue share
• Oncology dominated over a decade and is projected to sustain its share over the forecast period.
• Rising incidence of cancer and other chronic multi-drug resistant diseases pronounces the demand for these particles.
• Aforementioned factor is anticipated to drive targeted delivery with fastest YoY growth
• Asia Pacific is projected to showcase lucrative progress in the coming years
• Key countries in the region are working to enhance the patient’s reach to nanotechnology-based solutions
• Moreover, continuous support from the government bodies pertaining to initiation of new projects is expected to play crucial role for projected CAGR
• Key players contributing in this market are Pfizer Inc., Brigham Women’s Hospital (BWH), Immunolight LLC, nanoComposix, Nanobiotix, Nanospectra Biosciences, Inc, Merck KGaA, and AstraZeneca
• These participants are investing in development of the product portfolio that can target the chronic disorders
• Arrowhead Pharmaceuticals, Cytimmune Sciences, Inc, Nanobiotix, Celgene Corporation, Siteman Center of Cancer Nanotechnology Excellence (Washington University CCNE), and BIND Biosciences are few companies that have products in the pipeline phase

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the Nanoparticles – Metal & Metal Oxides in Healthcare Market on the basis of type, application, and region:

Nanoparticles – Metal & Metal Oxides Type Outlook (Revenue, USD Billion, 2013 – 2025)

• Gold Nanoparticles
• Silver Nanoparticles
• Iron Oxide Nanoparticles
• Alumina Nanoparticles
• Gadolinium Oxide Nanoparticles
• Others

Nanoparticles – Metal & Metal Oxides Application Outlook (Revenue, USD Billion, 2013 – 2025)

• In-vivoImaging
• Targeted Drug Delivery
• Proton Therapy
• In-vitro Assays
• Cell & Phantom Imaging

Nanoparticles – Metal & Metal Oxides Regional Outlook (Revenue, USD Billion, 2014 – 2025)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)

Access Press Release of Nanoparticles – Metal & Metal Oxides Market @ www.grandviewresearch.com/press-release/global-nanoparticles-metal-oxides-in-healthcare-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com